Intrinsic Value

The intrinsic value of ViroGates A/S (EP2) under the Base Case is 0.683 EUR per share. Compared with the current market price of 0.795 EUR, the stock appears Overvalued by 14% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

EP2 Intrinsic Value
€0.683
Overvaluation 14%
Intrinsic Value
Price €0.795

EP2 is cheaper than usual. Still overvalued, but at its cheapest valuation in the past 2 years.

Alert me when EP2 is below its intrinsic value
Today €0.547 · 31.2% below the current price
Alternatives to EP2

Fundamental Analysis

What ViroGates A/S Does

Health Care

ViroGates A/S is a Danish medical diagnostics company that sells tests for measuring the suPAR biomarker in blood. Its main product family, suPARnostic, is used to help doctors assess a patient’s risk of serious illness and to support decisions about treatment and hospital care. The company does not make broad healthcare devices; it focuses on this one biomarker-based testing niche.

Headquarters
Denmark DK
Employees
28
IPO date
Jun 26, 2018
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue EP2 Research

Decided on ViroGates A/S? Get an email when EP2 reaches the price you’d buy at. Free with an account.

Other ViroGates A/S listings

What is the Intrinsic Value of one EP2 stock?

The intrinsic value for ViroGates A/S (EP2) under the Base Case is 0.683 EUR.

Is EP2 stock undervalued or overvalued?

Compared with the current market price of 0.795 EUR, the stock appears Overvalued by 14% .

How reliable are our estimates? See how past valuations played out
Back to Top